Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer (primary tumor may be present)~2. Patients with at least one measurable lesion, with size \> 1 cm (RECIST v1.1)~3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)~4. Patients, who are able to tolerate intensive first lien treatment as judged by the investigator~5. Life expectancy \> 3 months~6. Age ≥ 18 years~7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin~   * 9 g/dl or 5.59 mmol/l~8. Patients not receiving therapeutic anticoagulation must have an INR \< 1.5 ULN and aPTT \< 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.~9. Adequate liver function as measured by serum transaminases (AST \& ALT) ≤ 2.5 x ULN (in case of liver metastases \< 5 x ULN) and total bilirubin ≤ 1.5 x ULN~10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN~11. Signed, written informed consent~Exclusion Criteria:~1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer (primary tumor may be present)~2. Patients with at least one measurable lesion, with size \> 1 cm (RECIST v1.1)~3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)~4. Patients, who are able to tolerate intensive first lien treatment as judged by the investigator~5. Life expectancy \> 3 months~6. Age ≥ 18 years~7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin~   * 9 g/dl or 5.59 mmol/l~8. Patients not receiving therapeutic anticoagulation must have an INR \< 1.5 ULN and aPTT \< 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.~9. Adequate liver function as measured by serum transaminases (AST \& ALT) ≤ 2.5 x ULN (in case of liver metastases \< 5 x ULN) and total bilirubin ≤ 1.5 x ULN~10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN~11. Signed, written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FOLFOX+Bevacizumab (Type: ACTIVE_COMPARATOR): bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
- FOLFOX+Bevacizumab+Irinotecan (Type: EXPERIMENTAL): bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)

Based on this trial design, predict the completion outcome and termination type (if applicable).